Liste des publications

Toutes les publications des équipes du C3M.

Exporter en CSV
Hallucination Rates and Reference Accuracy of ChatGPT and Bard for Systematic Reviews: Comparative Analysis.

Auteurs Chelli M, Descamps J, Lavoué V, Trojani C, Azar M, Deckert M, Raynier JL, Clowez G, Boileau P, Ruetsch-Chelli C

Journal of medical Internet research May 2024

The mechanical phenotypic plasticity of melanoma cell: an emerging driver of therapy cross-resistance.

Auteurs Diazzi S, Tartare-Deckert S, Deckert M

Oncogenesis Feb 2023

The mechanosensitive TRPV2 calcium channel promotes human melanoma invasiveness and metastatic potential.

Auteurs Shoji KF, Bayet E, Leverrier-Penna S, Le Devedec D, Mallavialle A, Marionneau-Lambot S, Rambow F, Perret R, Joussaume A, Viel R, Fautrel A, Khammari A, Constantin B, Tartare-Deckert S, Penna A

EMBO reports Feb 2023

Sphingosine-1 Phosphate Receptor Modulators Increase In Vitro Melanoma Cell Line Proliferation at Therapeutic Doses Used in Patients with Multiple Sclerosis.

Auteurs Ruetsch-Chelli C, Okuda DT, Rocher F, Tartare-Deckert S, Deckert M, Lebrun-Frenay C

Neurology and therapy Dec 2022

Role of extracellular matrix architecture and signaling in melanoma therapeutic resistance.

Auteurs Popovic A, Tartare-Deckert S

Frontiers in oncology Sep 2022

The Stress-Responsive microRNA-34a Alters Insulin Signaling and Actions in Adipocytes through Induction of the Tyrosine Phosphatase PTP1B.

Auteurs Cornejo PJ, Vergoni B, Ohanna M, Angot B, Gonzalez T, Jager J, Tanti JF, Cormont M

Cells Aug 2022

Emerging Role of Deubiquitinating Enzymes (DUBs) in Melanoma Pathogenesis.

Auteurs Ohanna M, Biber P, Deckert M

Cancers Juil 2022

Secretion of IL1 by Dedifferentiated Melanoma Cells Inhibits JAK1-STAT3-Driven Actomyosin Contractility of Lymph Node Fibroblastic Reticular Cells.

Auteurs Rovera C, Berestjuk I, Lecacheur M, Tavernier C, Diazzi S, Pisano S, Irondelle M, Mallavialle A, Albrengues J, Gaggioli C, Girard CA, Passeron T, Deckert M, Tartare-Deckert S, Prod'homme V

Cancer research May 2022

Discoidin Domain Receptor 2 orchestrates melanoma resistance combining phenotype switching and proliferation.

Auteurs Sala M, Allain N, Moreau M, Jabouille A, Henriet E, Abou-Hammoud A, Uguen A, Di-Tommaso S, Dourthe C, Raymond AA, Dupuy JW, Gerard E, Dugot-Senant N, Rousseau B, Merlio JP, Pham-Ledart A, Vergier B, Tartare-Deckert S, Moreau V, Saltel F

Oncogene Mar 2022

Blockade of the pro-fibrotic reaction mediated by the miR-143/-145 cluster enhances the responses to targeted therapy in melanoma.

Auteurs Diazzi S, Baeri A, Fassy J, Lecacheur M, Marin-Bejar O, Girard CA, Lefevre L, Lacoux C, Irondelle M, Mounier C, Truchi M, Couralet M, Ohanna M, Carminati A, Berestjuk I, Larbret F, Gilot D, Vassaux G, Marine JC, Deckert M, Mari B, Tartare-Deckert S

EMBO molecular medicine Feb 2022